Repertoire Immune Medicines
US-based Repertoire Immune Medicines pioneers in clinical trials for cancer and autoimmune disease treatments.
Founded
2015US-based Repertoire Immune Medicines pioneers in clinical trials for cancer and autoimmune disease treatments.
Repertoire Immune Medicines, founded in Cambridge, United States, is a clinical-stage biotechnology company dedicated to harnessing the human immune system to prevent, treat, or cure cancer, autoimmune conditions, and infectious diseases. The company focuses on discovering unique codes within the vast T cell repertoire and their interactions to develop transformative and programmable immune medicines. Currently, Repertoire is conducting experimental clinical trials using autologous T cells primed against cancer antigens and tethered to IL-15.
Notable affiliated individuals include leading scientists and clinicians in immunology and oncology. The company has attracted significant investment from prominent venture capital firms specializing in biotech innovations. Key achievements include advancing multiple candidates into clinical trials and pioneering novel approaches to immune system modulation. Repertoire Immune Medicines has made a substantial impact by pushing the boundaries of immunotherapy, aiming to deliver groundbreaking treatments for patients with severe diseases.
Companies similar to Repertoire Immune Medicines include Ernexa Therapeutics, Immunitas Therapeutics, Inimmune and Asylia Therapeutics.
Repertoire Immune Medicines was founded in 2015.
Repertoire Immune Medicines' headquarters is located in Cambridge, MA, US.
Repertoire Immune Medicines' most recent funding round was for $189M (USD) in April 2021.
As of Apr 13, 2021, Repertoire Immune Medicines has disclosed funding of $257.3M (USD). Undisclosed round amounts are excluded.
Repertoire Immune Medicines has 175 employees as of Feb 4, 2024.
Asylia Therapeutics
asyliatx.com
